網頁

Thursday, August 30, 2018

恒生香港35指数納入藥明生物


药明生物成为唯一入选恒生香港35指数的生物制药公司


香港,2018830——为客户提供发现、开发及生产生物制剂端对端解决方案的全球领先开放式的生物制剂技术平台公司——药明生物技术有限公司(“药明生物”或“公司”,股票代码:2269.HK),今日欣然宣布获纳入恒生香港35指数,910日起生效。

“恒生香港35指数”由主要营业收入来自中国以外的市值最大的35家香港上市公司组成。业界认为,该指数是反映香港大型股公司表现的高投资性指数,具有低波动性的特点,是投资者有效分散风险的最佳配置之选。

此次入选,充分彰显了药明生物作为一家国际化企业,其业务足迹遍布全球各地。药明生物于今年上半年启动“全球化”战略布局,分别在爱尔兰、新加坡、美国、中国等地宣布产能扩张计划以进一步巩固全球领先的行业地位,打造更高、更宽、更深的生物制药技术和能力平台,助力全球合作伙伴加快和变革生物药的发现、开发及生产,造福广大病患。

这也是继去年九月被纳入恒生综合指数、恒生医疗保健指数、恒生环球综合指数,和今年三月被纳入恒生港股通指数、恒生港股通中小型股指数、恒生港股通香港公司指数及恒生港股通非AH股公司指数后,药明生物在季度审核中再次获纳入新的恒生指数。


WuXi Biologics Selected into the Hang Seng HK 35 Index

Hong Kong, August 30, 2018 WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the company has been selected by Hang Seng Indexes as a constituent of the Hang Seng HK 35 Index (“HSHK35”) effective 10 September, 2018.

Hang Seng HK 35 comprises the 35 largest companies listed in Hong Kong market which derive the majority of their sales revenue from areas outside mainland China. The Hang Seng HK 35 provides a tradable index reflecting the performance of large-cap Hong Kong companies and it features low volatility which is the best choice for diversification.

WuXi Biologics’ inclusion in HSHK35 signifies that our company is recognized as a global company by the market. Besides China, WuXi Biologics has recently announced plans to execute our globalization strategy to build state-of-the-art manufacturing facilities in Ireland, Singapore and the U.S. WuXi Biologics will continue to focus on expanding our capabilities and capacities to enable our customers to transform biologics discovery, development and manufacturing to benefit patients worldwide.

Prior to joining the Hang Seng HK 35, WuXi Biologics was selected into Hang Seng Composite Index, Hang Seng Healthcare Index and Hang Seng Global Composite Index in September 2017, and was selected into Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng SCHK HK Companies Index and Hang Seng SCHK ex-AH Companies Index in March 2018.

About WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

No comments: